BIF-002

N/A

Report date: 2026/03/19 17:12:01

Base Information

Drug NameBIF-002

Drug Alias NameBIF-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Interleukin-1 receptor accessory proteinAnti-CD3

TargetsInterleukin-1 receptor accessory proteinT cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOstentus Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesOstentus Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A